Outpatient treatment with subcutaneous interleukin‐2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience

Abstract

This combination was feasible, well tolerated and manageable in an outpatient setting.

Effect of Haishengsu as an Adjunct Therapy for Patients with Advanced Renal Cell Cancer: A Randomized and Placebo-Controlled Clinical Trial

“…14 However, the triple therapies were associated with moderate to severe nausea and vomiting in almost all patients. 15 In the present study, there was no significant difference in the TNM staging of renal cell cancer between the HSS and the control group. Triple therapy was associated with a 51.9% response rate in the HSS group, and a 21.4% response rate in the control group.…”

Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

“…13 TAEAT does not always preclude continuation of the causative oncotherapeutic agent and may resolve quickly without treatment interruption, as shown for blinatumomab, tyrosine kinase inhibitors, interleukin (IL)-2, interferon-α, and fluorouracil. 14,15 However, regulatory restrictions and treatment guidelines that recommend (or mandate) treatment interruption/ discontinuation for asymptomatic ≥ G3 AST and ALT elevations can limit data generation for further identification and characterization of TAEAT. 16 Additional research is needed to establish criteria for isolated ≥ G3 AST and ALT elevations, so clinicians can differentiate between those that spontaneously resolve without consequences (ie, TAEAT) and those that may progress further to liver-related symptoms such as jaundice or acute or subacute hepatic failure, that is, coagulopathy (international normalized ratio [INR] ≥ 1.5) and new onset encephalopathy.…”

“…TAEAT does not always preclude continuation of the causative oncotherapeutic agent and may resolve quickly without treatment interruption, as shown for blinatumomab, tyrosine kinase inhibitors, interleukin (IL)–2, interferon-α, and fluorouracil 14,15. However, regulatory restrictions and treatment guidelines that recommend (or mandate) treatment interruption/discontinuation for asymptomatic ≥G3 AST and ALT elevations can limit data generation for further identification and characterization of TAEAT 16.…”